Trade Reata Pharma - RETA CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 172.17 |
| Open | 172.23 |
| 1-Year Change | 680.38% |
| Day's Range | 172.19 - 172.24 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 25, 2023 | 172.23 | 0.02 | 0.01% | 172.21 | 172.32 | 172.18 |
| Sep 22, 2023 | 172.17 | 0.00 | 0.00% | 172.17 | 172.19 | 172.11 |
| Sep 21, 2023 | 172.02 | -0.08 | -0.05% | 172.10 | 172.21 | 171.98 |
| Sep 20, 2023 | 172.07 | 0.10 | 0.06% | 171.97 | 172.07 | 171.97 |
| Sep 19, 2023 | 171.97 | 0.14 | 0.08% | 171.83 | 172.00 | 171.83 |
| Sep 18, 2023 | 171.90 | 0.08 | 0.05% | 171.82 | 171.93 | 171.60 |
| Sep 15, 2023 | 171.83 | -0.08 | -0.05% | 171.91 | 172.00 | 171.69 |
| Sep 14, 2023 | 171.92 | 0.05 | 0.03% | 171.87 | 171.93 | 171.84 |
| Sep 13, 2023 | 171.87 | 0.00 | 0.00% | 171.87 | 171.94 | 171.81 |
| Sep 12, 2023 | 171.83 | 1.44 | 0.85% | 170.39 | 171.91 | 170.08 |
| Sep 11, 2023 | 170.82 | 0.95 | 0.56% | 169.87 | 170.97 | 169.87 |
| Sep 8, 2023 | 170.15 | 0.58 | 0.34% | 169.57 | 170.23 | 169.57 |
| Sep 7, 2023 | 170.02 | 0.60 | 0.35% | 169.42 | 170.11 | 169.42 |
| Sep 6, 2023 | 169.51 | 0.34 | 0.20% | 169.17 | 169.60 | 169.05 |
| Sep 5, 2023 | 169.61 | 0.94 | 0.56% | 168.67 | 169.83 | 168.67 |
| Sep 1, 2023 | 169.13 | 0.31 | 0.18% | 168.82 | 169.36 | 168.82 |
| Aug 31, 2023 | 168.83 | 0.22 | 0.13% | 168.61 | 169.11 | 168.61 |
| Aug 30, 2023 | 168.53 | -0.22 | -0.13% | 168.75 | 169.03 | 168.53 |
| Aug 29, 2023 | 168.75 | -0.07 | -0.04% | 168.82 | 168.94 | 168.66 |
| Aug 28, 2023 | 168.77 | -0.10 | -0.06% | 168.87 | 169.17 | 168.71 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Reata Pharma Company profile
About Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. The Company's lead programs are in rare forms of chronic kidney disease and rare neurological disease. The Company’s Bardoxolone methyl and omaveloxolone products are in development for the treatment of several forms of chronic kidney disease and a severe neurologic disorder called Friedreich’s ataxia, respectively. The Company’s Technologies include Nrf2 Activators and HSP90 Modulators. Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. HSP90 Modulators developing a class of molecules that target pathways involved in the cellular stress response.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Reata Pharmaceuticals Inc revenues increased 27% to $11.5M. Net loss before extraordinary items increased 10% to $297.4M. Revenues reflect License and milestone increase of 71% to $8M. Higher net loss reflects Other Non Operating I/E increase from $21.9M to $46.7M (expense), General and administrative - Balancing increase of 44% to $65.8M (expense).
| Industry: | Biopharmaceuticals |
5320 Legacy Dr
PLANO
TEXAS 75024-3127
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com